Alterity Therapeutics Phase 2 Data Monitoring Committee
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,...
Source: globenewswire.com
Line Data Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Line Data Expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Line Data Expected Today - Breaking & Trending Today
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 -- Alterity Therapeutics , a...
Source: marketscreener.com
Alterity Therapeutics Phase 2 Data Monitoring Committee
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26,...
Source: globenewswire.com
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26, 2023 -- Alterity Therapeutics , a...
Source: marketscreener.com
Capricor Therapeutics Reports Fourth Quarter and Full Year
CAP-1002 Cell Therapy Programs -Pivotal Phase 3, HOPE-3 Trial Initiation Underway- -Entered Exclusive Partnership with Nippon Shinyaku for...
Source: globenewswire.com